TC BioPharm advances in acquisition strategy By Investing.com
EDINBURGH – TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company valued at approximately $5 million, has made significant strides in its acquisition negotiations, working towards expanding its gamma-delta T-cell therapies platform. According to InvestingPro data, the company’s stock has experienced significant volatility, declining over 98% in the past year. The company is actively pursuing acquisitions in the Natural Killer (NK) cell technologies and chimeric antigen receptor (CAR)-related technologies.
Earlier this year, TC BioPharm announced non-binding letters of intent with potential acquisition targets, signaling a strategic move to broaden its therapeutic reach. With an overall financial health score…
